• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究

丁小英 吴剑秋 张晓梅 汤唯艳 冯继锋 寇莹莹 汤依群

丁小英, 吴剑秋, 张晓梅, 汤唯艳, 冯继锋, 寇莹莹, 汤依群. 小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究[J]. 中华疾病控制杂志, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014
引用本文: 丁小英, 吴剑秋, 张晓梅, 汤唯艳, 冯继锋, 寇莹莹, 汤依群. 小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究[J]. 中华疾病控制杂志, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014
DING Xiao-ying, WU Jian-qiu, ZHANG Xiao-mei, TANG Wei-Yan, FENG Ji-feng, KOU Ying-ying, TANG Yi-qun. Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014
Citation: DING Xiao-ying, WU Jian-qiu, ZHANG Xiao-mei, TANG Wei-Yan, FENG Ji-feng, KOU Ying-ying, TANG Yi-qun. Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014

小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究

doi: 10.16462/j.cnki.zhjbkz.2016.06.014
基金项目: 

江苏省卫生计生委2015年度科研课题(H201511);江苏省2014年度普通高校研究生实践创新计划项目(SJLX-0290)

详细信息
    作者简介:

    丁小英(1988-),女,宁夏同心人,在读硕士研究生。主要研究方向:肿瘤药物不良反应监测。

  • 中图分类号: R730.267;R181

Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI

  • 摘要: 目的 探讨小分子第二代血管内皮生长因子受体抑制剂(vascular endothelial growth factor receptor tyrosine kinase inhibitor,VEGFR-TKI)治疗晚期肾透明细胞癌致甲状腺功能减低的发生及其疗效。方法 对2009年11月~2010年12月本院收治的24例晚期肾透明细胞癌患者,其中索拉非尼或阿昔替尼组10例,对照组(细胞因子)14例。分析甲状腺功能指标的变化趋势及其预后。结果 TKI组甲减的发生率50.0%,高于对照组甲减发生率7.1%(χ2=5.714,P=0.017)。甲减发生的中位生存时间56.2个月,甲功检测表现为促甲状腺激素明显升高伴血清游离甲状腺素(free thyroxine,FT4)同步下降,但游离三碘甲状腺原氨酸(free triiodothyronine,FT3)下降时间较为滞后。TKI组和对照组中位生存时间分别为:21.0个月(95% CI:0.001~54.200)和15.0个月(95% CI:4.000~26.000;P=0.265)。结论 小分子VEGFR-TKI治疗晚期转移性肾透明癌,TKI组甲减的发生率较对照组升高,生存时间较长。甲减可能是较常见的毒副反应,甲状腺功能的长期监测和甲减的适时干预,有助于提高患者治疗依从性和改善生存质量。
  • Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage:a new system to predict metastasis for patients with localized renal-cell-carcinomas [J]. Clin Cancer Res, 2008,14(17):5579-5584.
    Shariat SF, Bolenz C, Karakiewicz PI. Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double -blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators [J]. Eur Urol, 2008,54(4):948-949.
    Kakehi Y. Molecular targeted therapy for renal cell carcinoma [J]. Rinsho Ketsueki, 2008,49(8):622-625.
    Cella D, Cappelleri JC, Bushmakin A, et al. Quality of life predicts progression free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa [J]. J Oncol Pract, 2009,5(2):66-70.
    Culp SH, Wood CG. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double -blind, randomized, placebo controlled phase III trial [J]. Eur Urol,2009,55(6):1484-1485.
    Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma [J]. Drugs R D, 2011,11(2):113-126.
    Wilhelm S, Chien DS. BAY 43-9006: preclinical data [J]. Curr Pharm Des, 2002,8(25):2255-2257.
    Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms [J]. Cancer Treat Rev, 2014,40(7):883-891.
    Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow [J]. Oncologist, 2011,16(Suppl 2):45-50.
    Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal carcinoma [J]. J Clin Oncol, 2004,22(3):454-463.
    Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2014,25 Suppl 3:iii49-iii56.
    Peréz-Solert R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining [J]. J Clin Oncol, 2005,23(22):5235-5246.
    余国芳,林丽珠. 林丽珠辨治表皮生长因子受体抑制剂相关皮疹的经验探析 [J]. 世界科学技术˙中医药现代化, 2009,12(5):758-762.
    Grünwald V, Soltau J, Ivanyi P,et al. Molecular targeted therapies for solid tumors: management of side effects [J]. Onkologie. 2009,32(3):129-138.
    Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone and biomarkers: a phase I study in Japanese patients [J]. Cancer Sci, 2010,101(4):963-968.
    Viktor Grünwald, Axel S Merseburger. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [J]. Onco Targets Ther,2012,5:111-117.
    Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma:An expanded-access trial [J]. Lancet Oncol, 2009,10(8):757-763.
    Clemons J, Gao D, Naam M, et al. Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib [J]. Clin Genitourin Cancer, 2012,10(4): 225-231.
    Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in advanced renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial [J]. Jpn J Clin oncol, 2013,43(6):616-628.
  • 加载中
计量
  • 文章访问数:  265
  • HTML全文浏览量:  48
  • PDF下载量:  32
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-07
  • 修回日期:  2016-03-29

目录

    /

    返回文章
    返回